{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:15:13Z","timestamp":1789524913257,"version":"build-2803163510"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["P2022\/BMD-7229"],"award-info":[{"award-number":["P2022\/BMD-7229"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research, Development and Innovation Office of Hungary"},{"name":"National Heart Laboratory","award":["RRF-2.3.1-21-2022-00003"],"award-info":[{"award-number":["RRF-2.3.1-21-2022-00003"]}]},{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["#101016072"],"award-info":[{"award-number":["#101016072"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["965286"],"award-info":[{"award-number":["965286"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"COST","doi-asserted-by":"publisher","award":["IG16225"],"award-info":[{"award-number":["IG16225"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL131517"],"award-info":[{"award-number":["R01-HL131517"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL136389"],"award-info":[{"award-number":["R01-HL136389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL089598"],"award-info":[{"award-number":["R01-HL089598"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL163277"],"award-info":[{"award-number":["R01HL163277"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL160992"],"award-info":[{"award-number":["R01-HL160992"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cardiovascular diseases (CVD) remain the leading cause of death worldwide, and pharmacotherapy of most of them is suboptimal. Thus, there is a clear unmet clinical need to develop new pharmacological strategies with greater efficacy and better safety profiles. In this review, we summarize the most relevant advances in cardiovascular pharmacology in 2022, including the approval of first-in-class drugs that open new avenues for the treatment of obstructive hypertrophic cardiomyopathy (mavacamten), type 2 diabetes mellitus (tirzepatide), and heart failure (HF) independent of left ventricular ejection fraction (sodium-glucose cotransporter 2 inhibitors). We also dealt with fixed dose combination therapies repurposing different formulations of \u2018old\u2019 drugs with well-known efficacy and safety for the treatment of patients with acute decompensated HF (acetazolamide plus loop diuretics), atherosclerotic cardiovascular disease (moderate-dose statin plus ezetimibe), Marfan syndrome (angiotensin receptor blockers plus \u03b2-blockers), and secondary cardiovascular prevention (i.e. low-dose aspirin, ramipril, and atorvastatin), thereby filling existing gaps in knowledge and opening new avenues for the treatment of CVD. Clinical trials confirming the role of dapagliflozin in patients with HF and mildly reduced or preserved ejection fraction, long-term evolocumab to reduce the risk of cardiovascular events, vitamin K antagonists for stroke prevention in patients with rheumatic heart disease-associated atrial fibrillation, antibiotic prophylaxis in patients at high risk for infective endocarditis before invasive dental procedures, and vutrisiran for the treatment of hereditary transthyretin-related amyloidosis with polyneuropathy were also reviewed. Finally, we briefly discuss recent clinical trials suggesting that FXIa inhibitors may have the potential to uncouple thrombosis from haemostasis and attenuate\/prevent thromboembolic events with minimal disruption of haemostasis.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvad034","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T03:06:25Z","timestamp":1683860785000},"page":"353-370","source":"Crossref","is-referenced-by-count":31,"title":["New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-7758","authenticated-orcid":false,"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n , Plaza de Ram\u00f3n y Cajal s\/n, Madrid 28040 , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University , Oslo , Norvay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, University of Bologna-IRCCS AOU S. Orsola , Bologna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Ceconi","sequence":"additional","affiliation":[{"name":"Unit of Cardiologia, ASST Garda , Desenzano del Garda , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7839-1361","authenticated-orcid":false,"given":"Elisabetta","family":"Cerbai","sequence":"additional","affiliation":[{"name":"Department Neurofarba, Section of Pharmacology and Toxicology, University of Florence , Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gheorghe A","family":"Dan","sequence":"additional","affiliation":[{"name":"\u201cCarol Davila\u201d University of Medicine, Colentina University Hospital , Bucharest , Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest , Hungary"},{"name":"Pharmahungary Group , Szeged , Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aarhus University Hospital , Aarhus , Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health, Aarhus University , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"Section of Pharmacology, Catholic University School of Medicine , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5146-0099","authenticated-orcid":false,"given":"Patrick","family":"Sulzgruber","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Medical University of Vienna , Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Grete","family":"Semb","sequence":"additional","affiliation":[{"name":"Preventive Cario-Rheuma Clinic, Division of Research and Innovation, REMEDY Centre, Diakonhjemmet Hospital , Oslo , Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Sossalla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Regensburg , Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Niessner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-0189","authenticated-orcid":false,"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Research Institute, St. George's, University of London , Cranmer Terrace, London SW17 0RE , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West-German Heart and Vascular Centre, University Duisburg-Essen , Essen , Germany"},{"name":"Department of Medicine, Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al , Montr\u00e9al , Canada"},{"name":"Department of Molecular Physiology & Biophysics, Baylor College of Medicine , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2023060210535342800_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"key":"2023060210535342800_bib2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jacc.2021.11.021","article-title":"Management of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib3","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.jacc.2020.08.044","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive Summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib4","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/cvr\/cvaa124","article-title":"Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy","volume":"116","author":"Coppini","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2023060210535342800_bib5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/13543784.2022.2113374","article-title":"Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline","volume":"31","author":"Tamargo","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"key":"2023060210535342800_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","article-title":"Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light","volume":"10","author":"Trivedi","year":"2018","journal-title":"Biophys Rev"},{"key":"2023060210535342800_bib7","doi-asserted-by":"crossref","first-page":"a023200","DOI":"10.1101\/cshperspect.a023200","article-title":"Muscle Contraction","volume":"10","author":"Sweeney","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023060210535342800_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflugers Arch: Eur J Physiol"},{"key":"2023060210535342800_bib9","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J Biol Chem"},{"key":"2023060210535342800_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"2023060210535342800_bib11","doi-asserted-by":"crossref","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","article-title":"Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca2+ flux caused by thin filament hypertrophic cardiomyopathy mutations","volume":"318","author":"Sparrow","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023060210535342800_bib12","doi-asserted-by":"crossref","first-page":"101429","DOI":"10.1016\/j.cpcardiol.2022.101429","article-title":"Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2023060210535342800_bib13","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","article-title":"Mavacamten: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2023060210535342800_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib15","article-title":"CAMZYOSTM (mavacamten) capsules for oral us: US prescribing information","year":"2022"},{"key":"2023060210535342800_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2023060210535342800_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2023060210535342800_bib18","doi-asserted-by":"crossref","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023060210535342800_bib19","doi-asserted-by":"crossref","first-page":"21179","DOI":"10.1038\/s41598-021-00654-3","article-title":"The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs","volume":"11","author":"\u00d8stergaard","year":"2021","journal-title":"Sci Rep"},{"key":"2023060210535342800_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2023060210535342800_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023060210535342800_bib22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"2023060210535342800_bib23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"2023060210535342800_bib24","article-title":"MounjaroTM (tirzepatide) injection, for subcutaneous use: US prescribing information","year":"2022"},{"key":"2023060210535342800_bib25","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib28","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/jamacardio.2022.3750","article-title":"Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial","volume":"7","author":"Vaduganathan","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2023060210535342800_bib29","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-8587(22)00308-4","article-title":"Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"Inzucchi","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023060210535342800_bib30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O'Donoghue","year":"2022","journal-title":"Circulation"},{"key":"2023060210535342800_bib32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib34","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib35","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2022.06.030","article-title":"Antibiotic prophylaxis against infective endocarditis before invasive dental procedures","volume":"80","author":"Thornhill","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2023060210535342800_bib37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2023060210535342800_bib38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"key":"2023060210535342800_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2023060210535342800_bib40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"2023060210535342800_bib41","first-page":"1","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2022","journal-title":"Amyloid"},{"key":"2023060210535342800_bib42","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib43","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehac464","article-title":"Factor XI inhibitors: cardiovascular perspectives","volume":"44","author":"De Caterina","year":"2023","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib44","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.blre.2018.04.001","article-title":"Plasma contact factors as therapeutic targets","volume":"32","author":"Tillman","year":"2018","journal-title":"Blood Rev"},{"key":"2023060210535342800_bib45","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2023060210535342800_bib46","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"key":"2023060210535342800_bib47","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib48","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib49","first-page":"273","article-title":"Integrative assessment of congestion in heart failure throughout the patient journey","volume":"6","author":"Girerd","year":"2018","journal-title":"JACC: Heart Fail"},{"key":"2023060210535342800_bib50","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib51","first-page":"56","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ: Heart Fail"},{"key":"2023060210535342800_bib52","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/0002-8703(55)90081-8","article-title":"Studies on the continuous use of a carbonic anhydrase inhibitor (diamox) in ambulatory patients","volume":"49","author":"Massumi","year":"1955","journal-title":"Am Heart J"},{"key":"2023060210535342800_bib53","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s40261-017-0577-1","article-title":"Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study","volume":"37","author":"Imiela","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2023060210535342800_bib54","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ejhf.1478","article-title":"Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance","volume":"21","author":"Verbrugge","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2023060210535342800_bib55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/AC.70.3.3080630","article-title":"Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload","volume":"70","author":"Verbrugge","year":"2015","journal-title":"Acta Cardiol"},{"key":"2023060210535342800_bib56","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjhyper.2005.09.014","article-title":"Renal circulatory effects of acetazolamide in patients with essential hypertension","volume":"19","author":"Horita","year":"2006","journal-title":"Am J Hypertens"},{"key":"2023060210535342800_bib57","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1159\/000354515","article-title":"Hypoxia-inducible factor-1\u03b1 dependent pathways mediate the renoprotective role of acetazolamide against renal ischemia-reperfusion injury","volume":"32","author":"An","year":"2013","journal-title":"Cell Physiol Biochem"},{"key":"2023060210535342800_bib58","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1681\/ASN.2015121312","article-title":"Small-molecule inhibitors of pendrin potentiate the diuretic action of furosemide","volume":"27","author":"Cil","year":"2016","journal-title":"JASN"},{"key":"2023060210535342800_bib59","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","article-title":"Acetazolamide in acute decompensated heart failure with volume overload","volume":"387","author":"Mullens","year":"2022","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib60","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"2023060210535342800_bib61","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2023060210535342800_bib63","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"2023060210535342800_bib64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/M13-2526","article-title":"Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review","volume":"160","author":"Gudzune","year":"2014","journal-title":"Ann Intern Med"},{"key":"2023060210535342800_bib65","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.atherosclerosis.2014.10.105","article-title":"Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis","volume":"237","author":"Ambegaonkar","year":"2014","journal-title":"Atherosclerosis"},{"key":"2023060210535342800_bib66","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2023060210535342800_bib67","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.amjcard.2018.06.034","article-title":"Causes of Mortality in the Marfan syndrome (from a Nationwide Register Study)","volume":"122","author":"Groth","year":"2018","journal-title":"Am J Cardiol"},{"key":"2023060210535342800_bib68","first-page":"71","article-title":"Angiotensin, transforming growth factor \u03b2 and aortic dilatation in Marfan syndrome: of mice and humans","volume":"18","author":"Yu","year":"2018","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2023060210535342800_bib69","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(22)01534-3","article-title":"Angiotensin receptor blockers and \u03b2 blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials","volume":"400","author":"Pitcher","year":"2022","journal-title":"Lancet North Am Ed"},{"key":"2023060210535342800_bib70","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"2023060210535342800_bib71","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa2028220","article-title":"Polypill with or without aspirin in persons without cardiovascular disease","volume":"384","author":"Yusuf","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib72","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(21)01827-4","article-title":"Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis","volume":"398","author":"Joseph","year":"2021","journal-title":"Lancet North Am Ed"},{"key":"2023060210535342800_bib73","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0167-5273(15)31028-7","article-title":"The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention","volume":"201","author":"Tamargo","year":"2015","journal-title":"Int J Cardiol"},{"key":"2023060210535342800_bib74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cjca.2014.02.016","article-title":"Evolution of the polypill concept and ongoing clinical trials","volume":"30","author":"Castellano","year":"2014","journal-title":"Can J Cardiol"},{"key":"2023060210535342800_bib75","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill strategy in secondary cardiovascular prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N Engl J Med"},{"key":"2023060210535342800_bib76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic effects of statins on the cardiovascular system","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ Res"},{"key":"2023060210535342800_bib77","doi-asserted-by":"crossref","first-page":"21A","DOI":"10.1016\/j.amjcard.2009.10.010","article-title":"Are there effects of renin-angiotensin system antagonists beyond blood pressure control?","volume":"105","author":"Bakris","year":"2010","journal-title":"Am J Cardiol"},{"key":"2023060210535342800_bib78","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jacc.2016.06.005","article-title":"Assessing the impact of medication adherence on long-term cardiovascular outcomes","volume":"68","author":"Bansilal","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2023060210535342800_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijcard.2022.05.015","article-title":"The CNIC-polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study","volume":"361","author":"Gonz\u00e1lez-Juanatey","year":"2022","journal-title":"Int J Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad034\/50450605\/pvad034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/4\/353\/50508252\/pvad034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/9\/4\/353\/50508252\/pvad034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T21:29:54Z","timestamp":1685741394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/9\/4\/353\/7160449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":79,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5,11]]},"published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad034","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,5,11]]}}}